The FDA has approved Coagadex (coagulation factor X human), from Bio Products Lab, for hereditary Factor X deficiency. Until this...
Fujifilm Sonocare has announced CE mark approval for its newest generation of point-of-care ultrasound the X-Porte ultrasound kiosk. X-Porte uses...
Bio Products Laboratory Limited has presented new data from TEN02, the Phase III, prospective study of Coagadex (Coagulation Factor X,...
Philips launches Ingenia Ambition X 1.5T MR with industry-first fully sealed magnet for more productive, helium-free operations. Royal Philips has...
The FDA has accepted for filing a supplemental Biologics License Application (BLA) for Coagadex (Coagulation Factor X, Human), from Bio...
The FDA announced that the Mobilett Mira, a portable digital X-ray system from Siemens, has received 510(k) approval. The Mira�s...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Bio Products Laboratory, Limited has announced that the European Medicines Agency has granted marketing authorisation for Coagadex. Coagadex is indicated...
Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: - Treatment in monotherapy of infantile spasms (West's syndrome). - Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.